1Y Annualised Return
▼-19.81%
3Y Annualised Return
▲42.23%
5Y Annualised Return
▲20.10%
10Y Annualised Return
▲13.89%
SMS Pharmaceuticals Stock Performance
|
|
|
SMS Pharmaceuticals Company background
Founded in: 1987
Managing director: P Ramesh Babu
SMS Pharmaceuticals Limited was incorporated in December, 1987. The company is engaged in the business of manufacturing of Active Pharma Ingredients and their intermediates. Apart from R D Center at Gagillapur, Hyderabad, the company is having manufacturing facilities at Bachupally, Hyderabad and also at Kandivalasa Village in Vijayanagaram District of Andhra Pradesh.During the year 2015, the company has reenforced its fundamental strength of FDA compliant facilities by successfully completing the US FDA audits at Kandivalasa and Bachupally facilities.During the year 2015, the company filed 9 Drug Master Files and total DMFs filed up to 31 March 2015 are 24.During the year 201415, the Company acquired 12,25,900 equity shares of Rs. 10/ each in M/s. VKT Pharma Private Limited. With this the said company has become an associate company. The project of the said associate company is in final stage and at the verge of completion and operations are yet to be commenced. The Company has not having any subsidiaries.During the year 201516, the Company had sub divided the face value of share of Rs 10/ each into face value of Rs 1/ of each with record date of 18th December 2015.During FY 201516, the Board has approved the Draft Scheme of Arrangement for Demerger of Semi Regulated Units (Unit I, IV V) along with other Assets to transfer the same to SMS Lifesciences India Limited (Resulting Company), with an object to reduce the impact of Semi Regulated Units on Regulated Units, achieving operational efficiencies, site synergies and streamlining its current structure. The Draft Scheme of Arrangement is subject to the Approvals of Stock Exchanges, Securities Board of India Limited, Reserve Bank of India and other regulatory authorities and also Honble High Court of Judicature at Hyderabad for the State of Telangana and Andhra Pradesh.During FY 201617, the Company had made investment in its associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 201617, the Company had acquired 5,11,400 equity shares of face value of Rs 10/ each in the said associate at an average price of Rs 157.21. Further, the Company had also made an investment in 1000 equity shares of Sireen Drugs Private Limited of Rs 10/ each.SMS Lifesciences India Limited is the wholly owned subsidiary of the Company during the Financial Year 201617.The Semi Regulatory Units of the Company were demerged and transferred to SMS Lifesciences India Limited effective from 01042016 and SMS LifeSciences India Limited was made a Wholly Owned Subsidiary of the Company in 2017. The said Scheme became effective from 17th May, 2017. In terms of the said Scheme, the Company allotted 30,23,287 equity shares of Rs.10/ each to the shareholders of the company on 23rd June, 2017.The Company had made investment in its associate company viz. M/s. VKT Pharma Private Limited for its business purpose. During the year under review 201718, the Company had acquired 7,84,100 equity shares of face value of Rs.10/ each in the said associate at an average price of Rs.200.81.During FY 201819, the Company had made investment in its associate Company viz. M/s. VKT Pharma Private Limited for its business purpose. The Company held 38,50,165 equity shares of Rs 10/ each in VKT Pharma Private Limited as on 31st March 2019 as investments.In 202021, the Company incorporated Joint Venture (JV) in Spain with nomenclature of CHEMO SMS ENTERPRISES SL in the capital ratio of 55:45. The Ibuprofen product got launched in 2023.
SMS Pharmaceuticals Financial Highlights
SMS Pharmaceuticals reported a Q1 FY 2025-26 revenue of ₹196.05 crore, up 10.5% YoY, with net profit increased 37.0% to ₹18.71 crore. For the full year FY2025–2026, revenue reached ₹788.97 crore and profit touched at ₹67.4 crore. As of Jun '25, SMS Pharmaceuticals’s market capitalisation stood at ₹2,080.84 crores. Shareholding as of Jun '25 shows promoters holding 66.3%, with FIIs at 3%, DIIs at 30.7%, and public at %.
As of 14 Aug, 2025, SMS Pharmaceuticals share price is ₹234.7. The stock opened at ₹234 and had closed at ₹233.8 the previous day. During today’s trading session, SMS Pharmaceuticals share price moved between ₹232.66 and ₹235.50, with an average price for the day of ₹234.08. Over the last 52 weeks, the stock has recorded a low of ₹176.05 and a high of ₹398.00. In terms of performance, SMS Pharmaceuticals share price has increased by 18.2% over the past six months and has declined by 19.81% over the last year.
SMS Pharmaceuticals SIP Return Calculator
Over the past
1 year
3 years
5 years
Total Investment of ₹65,00,000
Would have become ₹58,94,201 (-9.32%)
Daily SIP of ₹25,000 would have become ₹58,94,201 in 1 year with a gain of ₹-6,05,798 (-9.32%)
SMS Pharmaceuticals Fundamental
Market Cap (in crs)
2,080.84
Face Value
1
Turnover (in lacs)
45.27
Key Metrics
Qtr Change %
41.03% Fall from 52W High
-9.4
Dividend yield 1yr %
Low in industry
0.2
SMS Pharmaceuticals Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
SMS Pharmaceuticals Quarterly Revenue
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
196.05 Cr | 248.2 Cr | 173.35 Cr | 196.75 Cr | 164.45 Cr |
SMS Pharmaceuticals Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
788.97 Cr | 713.72 Cr | 526.94 Cr | 525.07 Cr | 566.63 Cr | 417.06 Cr |
SMS Pharmaceuticals Quarterly Net Profit/Loss
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
18.71 Cr | 20.08 Cr | 17.08 Cr | 13.86 Cr | 16.37 Cr |
SMS Pharmaceuticals Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
67.4 Cr | 49.2 Cr | 3.88 Cr | 67.88 Cr | 60.96 Cr | 32.69 Cr |
SMS Pharmaceuticals Result Highlights
Result Summary
-
SMS Pharmaceuticals Ltd reported a 20.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 18.6%.
-
Its expenses for the quarter were down by 23.7% QoQ and up 19.6% YoY.
-
The net profit increased 18.6% QoQ and increased 24.3% YoY.
-
The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 2.3 during Q1 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
SMS Pharmaceuticals Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
0.00
Current Price
5Day EMA
230.80
10Day EMA
229.80
12Day EMA
230.10
20Day EMA
232.20
26Day EMA
233.70
50Day EMA
236.90
100Day EMA
237.70
200Day EMA
237.40
5Day SMA
230.50
10Day SMA
226.00
20Day SMA
233.50
30Day SMA
236.10
50Day SMA
239.70
100Day SMA
238.70
150Day SMA
227.30
200Day SMA
235.40
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 11806 Rs | 20550 Rs |
Week Rs | 39979 Rs | 84041 Rs |
Month Rs | 39447 Rs | 84166 Rs |
Resistance & Support
234.29
Pivot
Resistance
First Resistance
235.93
Second Resistance
237.13
Third Resistance
238.77
Support
First Support
233.09
Second support
231.45
Third Support
230.25
Relative Strength Index
50.91
Money Flow Index
53.42
MACD
-3.58
MACD Signal
-4.39
Average True Range
8.49
Average Directional Index
22.63
Rate of Change (21)
-4.31
Rate of Change (125)
17.35
SMS Pharmaceuticals Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
- | 1,992.38 | 544.1 | 862.6 | 685.70 | 3.37% | -4.16% | 12.58% | -6.10% | -18.33% | 0.67% | 36.60 | 40.57 | 6.11 | |
- | 1,786.50 | 106.04 | 190.97 | 170.68 | -4.27% | 10.56% | 28.75% | 54.03% | 120.93% | 0.30% | 25.25 | 40.57 | 1.68 | |
- | 2,541.96 | 42 | 100.9 | 47.31 | -6.83% | -26.06% | -10.46% | -20.85% | 33.69% | 0.43% | 34.13 | 40.57 | 2.15 | |
- | 2,340.44 | 744.95 | 1248 | 950.75 | 1.40% | -11.46% | 18.10% | -13.32% | 33.94% | 2.64% | 22.77 | 40.57 | 2.98 | |
Beta Drugs Ltd. | 1,915.00 | - | - | - | - | - | - | - | - | - | - | - | - | |
- | 2,189.31 | 665.1 | 1198.25 | 1,057.25 | 13.63% | 14.98% | 36.23% | 25.83% | 387.66% | 0.56% | 33.73 | 40.57 | 4.32 |
SMS Pharmaceuticals Share Price FAQs
How has SMS Pharmaceuticals shares performed in the past ?
SMS Pharmaceuticals share price in the past 1-year return was -15.79. The SMS Pharmaceuticals share hit a 1-year low of Rs. 176.05 and a 1-year high of Rs. 398.
What is the market cap of SMS Pharmaceuticals ?
The market cap of SMS Pharmaceuticals is Rs. 2080.84 Cr. as of 14/8/2025.
What is the current P/E ratio of SMS Pharmaceuticals ?
The PE ratios of SMS Pharmaceuticals is 29.58 as of 14/8/2025.
What is the current PB ratio of SMS Pharmaceuticals ?
The PB ratios of SMS Pharmaceuticals is 3.09 as of 14/8/2025
What is the Mutual Fund shareholding in SMS Pharmaceuticals ?
The Mutual Fund Shareholding in SMS Pharmaceuticals was 3.03% at the end of 14/8/2025.
How to buy SMS Pharmaceuticals shares?
You can easily buy SMS Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of SMS Pharmaceuticals ?
The 52-week high and low of SMS Pharmaceuticals share price is ₹398 and ₹176.05 as of 14/8/2025.
What is the EPS of SMS Pharmaceuticals ?
The earnings per share (EPS) of SMS Pharmaceuticals stood at 2.3 during Q1 FY 2025-26.
Please be aware that SMS Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account